 REDWOOD CITY, Calif., May 10, 2021 GLOBE NEWSWIRE -- Allakos Inc. the Company Nasdaq: ALLK, a biotechnology company developing lirentelimab AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. 